| Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer AJW Gibson, H Li, A D’Silva, RA Tudor, AA Elegbede, SM Otsuka, ... Medical Oncology 35, 1-8, 2018 | 47 | 2018 |
| A real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with extensive-stage SCLC in Canada AA Elegbede, AJ Gibson, AS Fung, WY Cheung, ML Dean, DG Bebb, ... JTO clinical and research reports 2 (12), 100249, 2021 | 23 | 2021 |
| Real-world adherence to guideline-recommended treatment for small cell lung cancer AA Elegbede, AJ Gibson, H Fu, ML Dean, DA Ezeife, H Lau, WY Cheung, ... American journal of clinical oncology 43 (4), 236-242, 2020 | 18 | 2020 |
| Impact of Asian ethnicity on outcome in metastatic EGFR‐mutant non–small cell lung cancer AJW Gibson, A D'Silva, AA Elegbede, RA Tudor, ML Dean, DG Bebb, ... Asia‐Pacific Journal of Clinical Oncology 15 (6), 343-352, 2019 | 17 | 2019 |
| Retrospective real-world outcomes for patients with ALK-rearranged lung cancer receiving ALK receptor tyrosine kinase inhibitors AJW Gibson, A Box, ML Dean, AA Elegbede, D Hao, R Sangha, DG Bebb JTO Clinical and Research Reports 2 (4), 100157, 2021 | 12 | 2021 |
| Comparison of clinical characteristics and outcomes in relapsed versus De novo metastatic non–small cell lung cancer AJW Gibson, H Li, A D’Silva, RA Tudor, AA Elegbede, S Otsuka, DG Bebb, ... American Journal of Clinical Oncology 42 (1), 75-81, 2019 | 12 | 2019 |
| Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: a 10 year population-based study AJW Gibson, H Li, A D’Silva, AA Elegbede, RA Tudor, S Otsuka, DG Bebb, ... Lung Cancer 134, 141-146, 2019 | 9 | 2019 |
| Real-world treatment patterns and effectiveness of targeted and immune checkpoint inhibitor-based systemic therapy in BRAF mutation-positive NSCLC AJW Gibson, A Pabani, ML Dean, G Martos, WY Cheung, V Navani JTO Clinical and Research Reports 4 (3), 100460, 2023 | 8 | 2023 |
| Real-World management and outcomes of crizotinib-treated ROS1-rearranged NSCLC: A retrospective Canadian Cohort AJW Gibson, A Box, WY Cheung, ML Dean, AA Elegbede, D Hao, ... Current Oncology 29 (3), 1967-1982, 2022 | 4 | 2022 |
| Molecular characteristics of BRAF mutated non-small cell lung cancer and therapeutic outcomes: Multi-institution study. G Martos, A Pabani, DG Bebb, AW Gibson, ML Dean, L Petersen Journal of Clinical Oncology 39 (15_suppl), e21029-e21029, 2021 | 3 | 2021 |
| The Population-based Impact of Adjuvant Chemotherapy on Outcomes in T2N0M0 Non–Small Cell Lung Cancer RK Arora, AW Gibson, DG Bebb, WY Cheung American Journal of Clinical Oncology 43 (7), 496-503, 2020 | 2 | 2020 |
| P16. 03 Early Mortality Associated Factors With Immune Checkpoint Inhibition in Real-World Canadian NSCLC Patients A Gibson, D Meyers, M Dean, I Stukalin, D Morris, DG Bebb Journal of Thoracic Oncology 16 (3), S348, 2021 | 1 | 2021 |
| P1. 03-043 30-Day Mortality Following Systemic Anti-Cancer Treatment for NSCLC at a Single Canadian Cancer Centre A Gibson, R Tudor, A D'Silva, A Elegbede, S Otsuka, H Li, G Bebb, ... Journal of Thoracic Oncology 12 (11), S1967, 2017 | 1 | 2017 |
| Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib AJW Gibson, ML Dean, I Litt, A Box, WY Cheung, V Navani Current Oncology 31 (5), 2427-2440, 2024 | | 2024 |
| EP06. 03-12 Characteristics, Treatment Patterns and Outcomes of Real-World NSCLC Exon 20 Insertions in HER1 (EGFR) and HER2 (ERBB2) A Gibson, A Box, M Dean, WY Cheung, V Navani Journal of Thoracic Oncology 18 (11), S487, 2023 | | 2023 |
| EP12. 03-01 Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy ML Dean, AJW Gibson, AH Box, WY Cheung, V Navani Journal of Thoracic Oncology 18 (11), S679-S680, 2023 | | 2023 |
| EP12. 03-02 Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA) LJ Zhan, S Barghout, S Raptis, F Al-Agha, A Popovacki, N Esfahanian, ... Journal of Thoracic Oncology 18 (11), S680, 2023 | | 2023 |
| EP12. 01-22 Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC A Gibson, M Dean, DY Heng, DE Meyers, Y Ruan, R Sangha, I Stukalin, ... Journal of Thoracic Oncology 18 (11), S649, 2023 | | 2023 |
| EP12. 01-42 Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort H Halperin, AJW Gibson, M Sung, P Tomasini, M Dean, J Law, ... Journal of Thoracic Oncology 18 (11), S657, 2023 | | 2023 |
| Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose … Annals of Oncology 34 (suppl_2), S954-S1000, 2023 | | 2023 |
